Ownership and insider activity for IGC Pharma, Inc. (IGC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
Price
| Price | $0.27 |
| Market Cap | $27M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-30 | Mukunda Ram | A-Award | 2,226,475 | $601K |
| 2026-06-30 | GRIMALDI CLAUDIA | A-Award | 2,048,378 | $553K |
| 2026-04-01 | PRINS RICHARD K | M-Exempt | 70,000 | |
| 2026-04-01 | PRINS RICHARD K | M-Exempt | 100,000 | |
| 2026-04-01 | PRINS RICHARD K | M-Exempt | 70,000 | |
| 2026-04-01 | PRINS RICHARD K | M-Exempt | 100,000 | |
| 2026-04-01 | Mukunda Ram | M-Exempt | 323,077 | $84K |
| 2026-04-01 | Mukunda Ram | M-Exempt | 333,333 | |
| 2026-04-01 | Mukunda Ram | M-Exempt | 33,332 | |
| 2026-04-01 | Mukunda Ram | M-Exempt | 16,667 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $538029 | $1.7M | $25.6M | $7.3M | $14.5M | $10.5M | $3.2M | $1.2M | $405000 | $207000 |
| Short-term Investments | $1.9M | 0 | 0 | $5.1M | $80000 | 0 | $154000 | 0 | 0 | $28000 |
| Receivables | $752926 | $557813 | $84000 | $133000 | $175000 | $597000 | $131000 | $91000 | $77000 | $37000 |
| Inventory | 0 | $486497 | $248000 | $4.2M | $7.2M | $3.5M | $2.7M | $1.5M | $1.4M | $638000 |
| Total Current Assets | $3.6M | $3.2M | $26.7M | $17.8M | $23.5M | $15.1M | $6.5M | $3.7M | $2.9M | $1.1M |
| Property, Plant & Equipment | $953936 | $6.2M | $5.9M | $10.4M | $11.3M | $9.9M | $8.5M | $3.9M | $3.3M | $2.1M |
| Goodwill | $198169 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $127826 | $184000 | $252000 | $407000 | $917000 | $1.2M | $1.6M | $1.9M | $5.3M |
| Total Assets | $11.3M | $10.9M | $34.5M | $29.0M | $35.9M | $26.8M | $17.2M | $9.9M | $8.7M | $9.2M |
| Accounts Payable | $416532 | $52270 | $319000 | $762000 | $476000 | $981000 | $530000 | $773000 | $883000 | $1.3M |
| Short-term Debt | 0 | $1.8M | $50000 | $50000 | $304000 | $3000 | 0 | 0 | $97000 | $726000 |
| Total Current Liabilities | $1.3M | $2.3M | $878000 | $1.9M | $2.4M | $2.4M | $1.9M | $2.3M | $2.3M | $2.9M |
| Long-term Debt | $2.6M | $427000 | 0 | 0 | $276000 | $144000 | $141000 | $137000 | $134000 | $191000 |
| Total Liabilities | $3.9M | $2.8M | $893000 | $2.4M | $3.1M | $2.9M | $2.3M | $2.6M | $2.4M | $3.1M |
| Retained Earnings | -$52.0M | -$53.8M | -$58.1M | -$65.4M | -$74.1M | -$89.2M | -$100.7M | -$113.7M | -$120.7M | -$127.3M |
| Total Equity | $7.4M | $8.1M | $33.6M | $26.5M | $32.8M | $23.9M | $14.9M | $7.3M | $6.3M | $6.1M |
| Total Debt | $2.6M | $2.2M | $50000 | $624000 | $1.1M | $611000 | $481000 | $345000 | $241000 | $926000 |
| Net Debt | $226277 | $569004 | -$25.6M | -$11.7M | -$13.6M | -$9.8M | -$2.9M | -$853000 | -$164000 | $691000 |
| Working Capital | $2.3M | $858993 | $25.8M | $15.8M | $21.1M | $12.7M | $4.6M | $1.4M | $639000 | -$1.7M |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 0.39 |
Profitability
| Return on Equity | -113.58% |
| Return on Invested Capital | -153.62% |
| Return on Assets | -83.03% |
| Gross Margin | 21.91% |
| Operating Margin | -986.82% |
| Net Margin | -702.14% |
Related companies: ANTX · BOLD · INTS · ITRM · NTRB · NXTC · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IGC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks